Evidence map›Paper›PMID 30668272›Full record

ArticleFly2018

Drosophila strain specific response to cisplatin neurotoxicity.

Christopher M Groen, Jewel L Podratz, Kevin Treb, Anthony J Windebank

Open access · bronzeAbstract read
In one paragraph

Article in Fly, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Genetic Reduction of Mitochondria Complex I Subunits is Protective against Cisplatin-Induced Neurotoxicity inThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  4. Cellular Pathogenesis of Chemotherapy-Induced Peripheral Neuropathy: Insights FromFrontiers in pain research (Lausanne, Switzerland) · 2022
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Christopher M Groena Department of Neurology , Mayo Clinic , Rochester , MN , USA.
Jewel L Podratza Department of Neurology , Mayo Clinic , Rochester , MN , USA.ORCID 0000-0002-2160-2022
Kevin Trebb Department of Medical Physics , University of Wisconsin , Madison , WI , USA.
Anthony J Windebanka Department of Neurology , Mayo Clinic , Rochester , MN , USA.
Mayo Clinic in Arizona · USUniversity of Wisconsin–Madison · US

Funding

Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
NIH HHS P40 OD018537
6 · The paper itself

Abstract

Drosophila melanogaster has recently been developed as a simple, in vivo, genetic model of chemotherapy-induced peripheral neuropathy. Flies treated with the chemotherapy agent cisplatin display both a neurodegenerative phenotype and cell death in rapidly dividing follicles, mimicking the cell specific responses seen in humans. Cisplatin induces climbing deficiencies and loss of fertility in a dose dependent manner. Drosophila sensitivity to cisplatin in both cell types is affected by genetic background. We show that mutation or RNAi-based knockdown of genes known to be associated with CIPN incidence in humans affect sensitivity of flies to CIPN. Drosophila is a promising model with which to study the effect of genetics on sensitivity to CIPN.

Indexed as

AnimalsAntineoplastic AgentsCisplatinDisease Models, AnimalDrosophilaNeurotoxicity SyndromesNeurotoxinsPeripheral Nervous System DiseasesToxicity TestsAntineoplastic AgentsCisplatinNeurotoxinsABC transporterchemotherapy-induced peripheral neuropathycisplatinDrosophilaglutathioneneurodegeneration

Identifiers

PMID30668272
PMCPMC6988872
OpenAlexW2914816800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.